Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3056217 | 0.88 | OPRD1 (0.49) | HRH3OPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL3066036 | 0.83 | HRH3 (0.45) | HRH3KCNH2CYP11B2CSNK2A1CYP1A2 | |
| SCHEMBL3060918 | 0.83 | L3MBTL3 (0.55) | HRH3ALDH1A1TSHR | |
| SCHEMBL1743034 | 0.82 | HRH3 (0.51) | KDM2BHRH3CYP11B2CYP1A2ALDH1A1 | |
| SCHEMBL3073537 | 0.81 | L3MBTL3 (0.53) | HRH3KCNH2 | |
| SCHEMBL3050856 | 0.81 | KDM2B (0.41) | KDM2BHRH3KCNH2CYP11B2CSNK2A1 | |
| SCHEMBL3060987 | 0.80 | KDM2B (0.43) | KDM2BHRH3 | |
| SCHEMBL1743162 | 0.80 | HRH3 (0.48) | KDM2BHRH3CYP11B2CYP1A2ALDH1A1 | |
| SCHEMBL3051150 | 0.79 | KDM2B (0.41) | KDM2BHRH3CYP11B2ALDH1A1CYP2D6 | |
| SCHEMBL3061192 | 0.79 | HRH3 (0.42) | HRH3KCNH2MAP4K1KDM5AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344001-B2 | Heterocyclic H3 antagonists | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-01-01 | — | — | US | claimed |
| US-20100267721-A1 | Heterocyclic H3 Antagonists | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-10-21 | — | — | US | claimed |
| US-8344001-B2 | Heterocyclic H3 antagonists | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344001-B2 | Heterocyclic H3 antagonists | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344001-B2 | Heterocyclic H3 antagonists | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100267721-A1 | Heterocyclic H3 Antagonists | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267721-A1 | Heterocyclic H3 Antagonists | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267721-A1 | Heterocyclic H3 Antagonists | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-10-21 | — | — | US | disclosed |
| EP-2166850-A1 | NEW HETEOCYCLIC H3 ANTAGONISTS | High Point Pharmaceuticals, LLC (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-2014656-A2 | New heteocyclic h3 antagonists | TRANSTECH PHARMA (US) | 2009-01-14 | — | — | EP | disclosed |
| EP-2014656-A2 | New heteocyclic h3 antagonists | TRANSTECH PHARMA (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008154126-A1 | NEW HETEOCYCLIC H3 ANTAGONISTS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008154126-A1 | NEW HETEOCYCLIC H3 ANTAGONISTS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267721-A1 | Heterocyclic H3 Antagonists | HRH3, HRH4, HRH2 | KDM2B 1958/4885HRH3 1/4885KCNH2 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.